Just like the novel coronavirus itself, the emergence of so-called long COVID has surprised both the patients who couldn’t shake their symptoms and the clinicians who have struggled to provide effective treatments. Now, as the U.S. looks to move past the pandemic, there remain unanswered questions about how this fallout from the virus might hamper some workers and for how long. These uncertainties could have important implications for workers’ compensation. By some measures, one in four patients who get COVID-19—even those with mild or asymptomatic cases—will experience subsequent symptoms that range from muscle and nerve pain to breathing difficulties to anxiety and depression. The scope of the challenge will require providers and employers to better understand the nature of the conditions, their origins, and the best paths for treatment. Watch this on-demand webinar to learn more about long COVID and the implications for workers and employers.
More stories
Mitchell Secures New Investment Partner in Stone Point Capital in its Continued Commitment to Growth and Innovation
KKR, and Elliott Management today announced that they have executed a definitive agreement under which funds managed by private equity firm Stone Point Capital LLC (“Stone Point”) are making an investment in Mitchell and acquiring the equity position held by KKR and Elliott Management.
Diagnostics Systems Key to Proper and Safe Repairs for Fountain Valley Body Shop
Since opening his Fountain Valley body shop over 40 years ago, owner Dave March has had a front row seat witnessing the evolution of the collision repair industry. In 1974 when his shop opened, only one automobile manufacturer offered airbags, and the NHTSA was still five years away from crash-testing popular cars to encourage manufacturers to improve the safety of their vehicles.
Pennsylvania House Passes Drug Formulary Bill
The Pennsylvania House justed passed a bill to establish a drug formulary. The bill is now awaiting action from Pennsylvania's governor.
StateWatch: Bill Review April 2018
Keep current with new legislation and its potential effect on your organization. This regulatory update is for informational purposes only, and provides some key highlights on state initiatives that may impact the bill review services Genex provides.
What’s BIG Diversity?
It’s mid-April, a time when my Outlook calendar begins to beep repeatedly in anticipation of the annual RIMS conference. While you surely have most of your regular appointments, sessions events scheduled by now, I’d suggest saving some time for a few new programs scheduled for the San Antonio meeting next week.
Texas Publishes Final Drug Formulary Rule Change
Texas published a formal rule change that re-defines compound medication.